At CTS, we understand the impact converting to the Ortho viral marker platform has on your operations. As we get closer to our implementation date of January 11, 2021 we are committed to providing you information as it becomes available.
Package inserts for the new assays are now available. You can review them on the Communications page by clicking this link: Communications,
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...